Emerging strategies to therapeutically target GATA2 in prostate cancer include the GATA2 small molecule inhibitor K7174 which suppresses the expression of AR, AR splice variants, and AR target genes via a posttranscriptional mechanism of inhibition (48). The gene discussed is GATA2; the disease is Familial prostate cancer.